TransMedics Group (NASDAQ:TMDX) Director David Weill Purchases 1,336 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill acquired 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

TransMedics Group Price Performance

TransMedics Group stock opened at $85.86 on Tuesday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The firm has a market cap of $2.97 billion, a PE ratio of 22.07, a price-to-earnings-growth ratio of 1.13 and a beta of 1.90. The company’s 50 day moving average is $82.29 and its two-hundred day moving average is $89.90.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm’s revenue was up 20.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.92 EPS. On average, research analysts expect that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. WINTON GROUP Ltd boosted its position in TransMedics Group by 52.4% in the second quarter. WINTON GROUP Ltd now owns 18,203 shares of the company’s stock valued at $1,209,000 after buying an additional 6,262 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of TransMedics Group by 31.3% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company’s stock valued at $191,000 after purchasing an additional 686 shares during the period. IFP Advisors Inc lifted its position in TransMedics Group by 4.8% during the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock worth $309,000 after buying an additional 213 shares in the last quarter. Corient Private Wealth LP lifted its stake in TransMedics Group by 123.2% in the second quarter. Corient Private Wealth LP now owns 19,285 shares of the company’s stock valued at $1,281,000 after acquiring an additional 10,644 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of TransMedics Group in the second quarter valued at $551,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TMDX. UBS Group lowered their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research note on Friday. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. TD Cowen reissued a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.